Oji Pharma

Oji Pharma is a specialized pharmaceutical subsidiary of the Japanese conglomerate Oji Holdings Corporation, established to commercialize healthcare innovations derived from wood-based resources. The company's primary focus is the development of a wood-derived sulfated cellulose, which serves as a sustainable, plant-based alternative to animal-derived heparin. This "wood-derived heparinoid" aims to provide a stable supply chain and reduce the risk of contamination associated with traditional porcine-sourced anticoagulants. Beyond its lead program, Oji Pharma explores the application of cellulose nanofibers and other wood-derived materials in drug delivery systems and medical devices. The company leverages the extensive R&D infrastructure of the Oji Group to bridge the gap between forestry science and advanced biotechnology.